Engineered immune cells take on Hard-to-Treat cancers in early trial
NCT ID NCT06767046
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a personalized cell therapy for people with advanced colorectal, pancreatic, or lung cancers that have a specific KRAS G12V mutation. The treatment involves taking a patient's own immune T cells, engineering them to recognize and attack cancer cells, and infusing them back. The study aims to check safety and see if the therapy can shrink tumors in just 8 participants who have run out of standard options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- KRAS-specific autologous TCR-T cells (CRTKVA11-N04) plus fludarabine, cyclophosphamide, and interleukin-2
- What this could lead to
- If successful, this could point toward a new treatment option for advanced solid tumors with the KRAS G12V mutation, potentially shrinking tumors or slowing disease progression.
- What could go wrong
- This is a very early (Phase 1) and small (8 participants) study focused mainly on safety. The treatment may not shrink tumors, and side effects could be serious, including immune reactions or organ damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Capital Medical University Affiliated Beijing Ditan Hospital
Beijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can High-Dose vitamin c boost Chemo's punch against pancreatic cancer?
- Can a cancer pill keep working outside the lab? a Real-World test begins
- Ancient acupressure meets modern medicine: can ear stimulation replace standard Anti-Nausea drugs?
- AI trained on thousands of pancreatic cancer cases could revolutionize diagnosis
- New oral drug targets Cancer's growth engine in advanced tumours
- New imaging compound targets Hard-to-Spot cancers